The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
 
Peter H. O'Donnell
Honoraria - Astellas Pharma; Axiom Healthcare Strategies; CLD, Inc.; Curio Science; EMD Serono; FirstWord; Great Debates and Updates; Institute for Enquiring Minds; IntrinsiQ; ISMIE; MedLearning Group; Merck; MJH Life Sciences; NAMCP; Peerview; Pfizer; Research to Practice; Seagen; Vaniam Group
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Expert Testimony - Oregon Health & Science University (OHSU)
Travel, Accommodations, Expenses - Curio Science
Other Relationship - Dragonfly Therapeutics; G1 Therapeutics; Janssen; Nektar; NIH
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Medscape; Medscape; Medscape; Medscape; MJH Life Sciences; MJH Life Sciences; MJH Life Sciences; MJH Life Sciences; Peerview; Peerview; Peerview; Peerview; Pfizer; Pfizer; Pfizer; Pfizer; Physicans' Education Resource; Physicans' Education Resource; Physicans' Education Resource; Physicans' Education Resource; Research To Practice; Research To Practice; Research To Practice; Research To Practice; UpToDate; UpToDate; UpToDate; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Alligator Bioscience; Alligator Bioscience; Alligator Bioscience; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; BioClin Therapeutics; BioClin Therapeutics; BioClin Therapeutics; BioClin Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Hengrui Pharmaceutical; Hengrui Pharmaceutical; Hengrui Pharmaceutical; Hengrui Pharmaceutical; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Imvax; Imvax; Imvax; Imvax; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Seagen; Seagen; Seagen; Seagen; Tyra Biosciences; Tyra Biosciences; Tyra Biosciences; Tyra Biosciences
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst); Predictor of platinum sensitivity (Inst); Predictor of platinum sensitivity (Inst); Predictor of platinum sensitivity (Inst)
 
Christopher J. Hoimes
Honoraria - Seagen; Seagen; Seagen; Seagen
Consulting or Advisory Role - 2bPrecise; 2bPrecise; 2bPrecise; 2bPrecise; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Prometheus; Prometheus; Prometheus; Prometheus; Seagen; Seagen; Seagen; Seagen
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Seagen; Seagen; Seagen; Seagen
Research Funding - Alkermes (Inst); Alkermes (Inst); Alkermes (Inst); Alkermes (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Dynavax Technologies (Inst); Dynavax Technologies (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); NeoImmuneTech (Inst); NeoImmuneTech (Inst); NeoImmuneTech (Inst); NeoImmuneTech (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst); 2bPrecise (Inst); 2bPrecise (Inst); 2bPrecise (Inst)
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Expert Testimony - Celgene; Celgene; Celgene; Celgene; sanofi; sanofi; sanofi; sanofi
 
Matthew I. Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; Loxo/Lilly
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); Alliance Foundation Trials (Inst); Alliance Foundation Trials (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); ALX Oncology (Inst); ALX Oncology (Inst); ALX Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Other Relationship - Elsevier; Elsevier; Elsevier; Elsevier; Medscape; Medscape; Medscape; Medscape
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; Astellas Medivation; Astellas Medivation; Astellas Medivation; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Caris Life Sciences; Caris Life Sciences; Caris Life Sciences; Caris Life Sciences; Dendreon; Dendreon; Dendreon; Dendreon; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Janssen; Janssen; Janssen; Merck; Merck; Merck; Merck; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Sorrento Therapeutics; Sorrento Therapeutics; Sorrento Therapeutics; Sorrento Therapeutics; Tempus; Tempus; Tempus; Tempus; Vividion Therapeutics; Vividion Therapeutics; Vividion Therapeutics; Vividion Therapeutics
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Tempus (Inst); Tempus (Inst); Tempus (Inst); Tempus (Inst)
 
Sandy Srinivas
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Seagen; Seagen; Seagen; Seagen
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst)
Other Relationship - Pfizer; Pfizer; Pfizer; Pfizer
 
Terence W. Friedlander
Leadership - Med BioGene; Med BioGene; Med BioGene; Med BioGene
Honoraria - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; EMD Serono; EMD Serono; EMD Serono; EMD Serono
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Basilea; Basilea; Basilea; Basilea; Dava Oncology; Dava Oncology; Dava Oncology; Dava Oncology; Dendreon; Dendreon; Dendreon; Dendreon; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Merck; Merck; Merck; Merck
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen; Janssen; Janssen; Janssen; Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics
 
Chethan Ramamurthy
Consulting or Advisory Role - Seagen; Seagen; Seagen; Seagen
Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Genomic Health; Genomic Health; Genomic Health; Genomic Health; Janssen; Janssen; Janssen; Janssen; Nektar; Nektar; Nektar; Nektar; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Genome & Company (Inst); Genome & Company (Inst); Genome & Company (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); NiKang Therapeutics (Inst); NiKang Therapeutics (Inst); NiKang Therapeutics (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Tricon Pharmaceuticals (Inst); Tricon Pharmaceuticals (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst)
 
Earle F Burgess
Stock and Other Ownership Interests - Arvinas; Arvinas; Arvinas; Arvinas; Becton Dickinson; Becton Dickinson; Becton Dickinson; Becton Dickinson; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Macrogenics; Macrogenics; Macrogenics; Macrogenics; Medtronic; Medtronic; Medtronic; Medtronic
Honoraria - Exelixis; Exelixis; Exelixis; Exelixis; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Pfizer; Pfizer; Pfizer; Pfizer
 
Nataliya Mar
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Aveo; Aveo; Aveo; Aveo; Eisai; Eisai; Eisai; Eisai; Seagen; Seagen; Seagen; Seagen; Tempus; Tempus; Tempus; Tempus
 
Helen Moon
Honoraria - EMD Serono; EMD Serono; EMD Serono; EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Apollomics (Inst); Apollomics (Inst); Apollomics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); HUYA Bioscience International (Inst); HUYA Bioscience International (Inst); HUYA Bioscience International (Inst); HUYA Bioscience International (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Prometheus; Prometheus; Prometheus; Prometheus; Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Pfizer; Pfizer; Pfizer; Pfizer; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Saby George
Consulting or Advisory Role - AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Sanofi; Sanofi; Sanofi; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Aravive (Inst); Aravive (Inst); Aravive (Inst); Aravive (Inst); Aveo (Inst); Aveo (Inst); Aveo (Inst); Aveo (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst); Surface Oncology (Inst); Surface Oncology (Inst); Surface Oncology (Inst)
 
Anne-Sophie Carret
Employment - Seagen; Seagen; Seagen; Seagen
Stock and Other Ownership Interests - Seagen; Seagen; Seagen; Seagen
Honoraria - Seagen; Seagen; Seagen; Seagen
Travel, Accommodations, Expenses - Seagen; Seagen; Seagen; Seagen
 
Yao Yu
Employment - Seagen; Seagen; Seagen; Seagen
Stock and Other Ownership Interests - Seagen; Seagen; Seagen; Seagen
 
Maria Guseva
Employment - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
 
Thomas W. Flaig
Leadership - Aurora Oncology; Aurora Oncology; Aurora Oncology; Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology; Aurora Oncology; Aurora Oncology; Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Seagen; Seagen; Seagen; Seagen
Research Funding - Agensys; Agensys; Agensys; Agensys; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; astrazeneca/MedImmune; astrazeneca/MedImmune; astrazeneca/MedImmune; astrazeneca/MedImmune; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Dendreon; Dendreon; Dendreon; Exelixis; Exelixis; Exelixis; Exelixis; GTx; GTx; GTx; GTx; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; La Roche-Posay; La Roche-Posay; La Roche-Posay; La Roche-Posay; Lilly; Lilly; Lilly; Lilly; Medivation; Medivation; Medivation; Medivation; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Sotio; Sotio; Sotio; Sotio; Tokai Pharmaceuticals; Tokai Pharmaceuticals; Tokai Pharmaceuticals; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.